Arvind Dasari, MD, MS, The University of Texas MD Anderson Cancer Center, Houston, TX, discusses the CIRCULATE-US trial, a part of the CIRCULATE study (NCT04089631), which aims to assess the use of ctDNA to detect minimal residual disease (MRD) in patients with colorectal cancer. Patients who are identified as MRD-negative postoperatively will be randomized to receive either immediate adjuvant chemotherapy, whereas MRD-positive patients following surgery will be randomized to receive either the current SOC for adjuvant chemotherapy (oxaliplatin and fluoropyrimidine) or more intensive chemotherapy via addition of irinotecan. This interview took place at the American Society of Clinical Oncology (ASCO) 2023 Gastrointestinal Cancers (GI) Symposium in San Francisco, CA.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
View our new feature exploring genomic biomarkers in metastatic colorectal cancer here: https://bit.ly/3DcSevZ